Have any approved or investigational anti-cancer therapy, including chemotherapy or hormonal therapy, with exceptions: Hormone-replacement therapy or oral contraceptives
Any approved anti-cancer therapy, including chemotherapy or hormonal therapy, within  weeks prior to initiation of study treatment
Treatment for this cancer including surgery, radiation therapy, chemotherapy, biotherapy, hormonal therapy or investigational agent prior to study entry
Any anti-cancer therapy, whether investigational or approved, including chemotherapy, hormonal therapy, or radiotherapy, within  weeks prior to initiation of study treatment
Prior treatment of this cancer including:\r\n* Surgery\r\n* Radiation therapy\r\n* Chemotherapy\r\n* Biotherapy\r\n* Hormonal therapy \r\n* Investigational agent prior to study entry
Any anti-cancer therapy, including chemotherapy or hormonal therapy, within  weeks prior to initiation of study treatment
Any approved anti-cancer therapy within  weeks prior to initiation of study treatment
Any approved anti-cancer therapy, including chemotherapy or hormonal therapy, within  weeks prior to initiation of study treatment, with the exceptions stated in the protocol
Any approved anti-cancer therapy, including chemotherapy, or hormonal therapy within  weeks prior to the initiation of study treatment. The following exceptions are allowed: hormone-replacement therapy or oral contraceptives
Any anti-cancer therapy including chemotherapy, hormonal therapy, or radiotherapy within  weeks prior to initiation of study treatment; or herbal therapy intended as anti-cancer therapy within  week prior to initiation of study treatment
Any approved anti-cancer therapy, including chemotherapy, or hormonal therapy within  weeks prior to initiation of study treatment; the following exceptions are allowed:\r\n* Palliative radiotherapy for bone metastases or soft tissue lesions should be completed >  days prior to baseline imaging\r\n* Hormone-replacement therapy or oral contraceptives
Treatment with any approved anti-cancer therapy, including chemotherapy, immunotherapy, radiopharmaceutical or hormonal therapy (with the exception of abiraterone), within  weeks prior to initiation of study treatment
Any approved anticancer therapy, including chemotherapy, or hormonal therapy (except hormone-replacement therapy or oral contraceptives) within  weeks of first dose.
Any anti-cancer therapy, including chemotherapy, hormonal therapy, or radiotherapy, within  weeks prior to initiation of study treatment (hormonal therapy with gonadotropin-releasing hormone agonists or antagonists for prostate cancer and palliative radiotherapy greater than (>)  weeks prior to Cycle , Day  are allowed)
Any anti-cancer therapy, whether investigational or approved, including chemotherapy, hormonal therapy, or radiotherapy, within  weeks prior to initiation of study treatment
Any approved anti-cancer therapy, including chemotherapy or hormonal therapy, within  weeks prior to initiation of study treatment, with the following exceptions: hormone-replacement therapy or oral contraceptives; tyrosine kinase inhibitors (TKIs) that have been discontinued >  days prior to cycle , day ; screening scans must be obtained after discontinuation of prior TKIs
Treatment for this cancer including surgery, radiation therapy, chemotherapy, biotherapy, hormonal therapy or investigational agent prior to study entry
Any approved anti-cancer therapy within  weeks prior to initiation of study treatment
Any approved anti-cancer therapy within  weeks prior to initiation of study treatment
Any approved anti-cancer therapy, including chemotherapy, or hormonal therapy within  weeks prior to initiation of study treatment; the following exception are allowed: Hormone-replacement therapy or oral contraceptives tyrosine-kinase inhibitors (TKIs) approved for treatment of NSCLC discontinued > days prior to Cycle , Day 
Any approved anti-cancer therapy, including chemotherapy, or hormonal therapy within  weeks prior to initiation of study treatment
Any major surgery =<  days prior to the initiation of investigational products, or received anti-cancer therapy (including chemotherapy, biological therapy, hormonal therapy, investigational agents, or other anti-cancer therapy) administered =<  days prior to the initiation of investigational products
Participants who have received anti-cancer therapy (including chemotherapy, biological therapy, investigational agents, hormonal therapy, or other anti-cancer therapy) or radiotherapy within =<  days prior to the planned initiation of investigational products, or those who have not recovered to grade =<  from adverse events due to their most recent therapy (excepting alopecia)
Treatment with chemotherapy, hormonal therapy (except hormone replacement therapy, oral contraceptives, or gonadotropin-releasing hormone (GnRH) agonists or antagonists for prostate cancer), immunotherapy, biologic therapy, radiation therapy (except palliative radiation to bony metastases), or herbal therapy as cancer therapy within  weeks prior to initiation of ipatasertib. Exceptions are kinase inhibitors approved by local regulatory authorities, which may be used within  weeks prior to initiation of ipatasertib, provided that any clinically-relevant drug-related toxicity has completely resolved and prior approval is obtained from the Medical Monitor
Any approved anticancer therapy, including chemotherapy, hormonal therapy, or radiotherapy, within  weeks prior to initiation of study treatment
Any systemic anti-cancer therapy (including hormonal therapy), radiation, or experimental agent =<  weeks of first dose of study treatment
Any of the following for treatment of this cancer including:\r\n* Surgery\r\n* Radiation therapy\r\n* Chemotherapy\r\n* Biotherapy\r\n* Hormonal therapy\r\n* Investigational agent prior to study entry
Treatment with any approved anti-cancer therapy within  weeks prior to the first dose of study treatment
Anti-tumor therapy, including chemotherapy, biologic, experimental, or hormonal therapy within  weeks prior to Day 
Use of any approved anti-cancer therapy within  weeks prior to treatment
Any approved anti-cancer therapy, including chemotherapy or hormonal therapy, within  weeks prior to initiation of study treatment
Any approved anti-cancer therapy, including chemotherapy, or hormonal therapy within  weeks prior to initiation of study treatment; the following exceptions are allowed:\r\n* Hormone-replacement therapy or oral contraceptives\r\n* TKIs approved for treatment of NSCLC discontinued >  days prior to cycle , day ; the baseline scan must be obtained after discontinuation of prior TKIs
Any anti-cancer therapy, whether investigational or approved, including chemotherapy, hormonal therapy, and/or radiotherapy, within  weeks prior to initiation of study treatment, with the exceptions as mentioned in the protocol
Treatment with anti-tumor therapy, including chemotherapy, biologic, experimental or hormonal therapy, within  weeks prior to Day 
Anti-tumor therapy, including chemotherapy, biologic, experimental, or hormonal therapy within  weeks prior to study treatment
Anti-tumor therapy, including chemotherapy, biologic, experimental, or hormonal therapy, or radiotherapy within  weeks prior to Day , with the following exceptions: maintenance hormonal therapy for metastatic prostate cancer and palliative radiation to bone metastases within  weeks prior to Day 
Any approved systemic anti-cancer therapy (including chemotherapy) or hormonal therapy within  weeks prior to initiation of study treatment
Any approved anti-cancer therapy, including chemotherapy or hormonal therapy, within  weeks prior to initiation of study treatment, with the exceptions provided in the protocol
Any approved anti-cancer therapy, including chemotherapy or hormonal therapy, within  weeks prior to initiation of study treatment